These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 29858367)

  • 1. Longitudinal Changes in Cholesterol Efflux Capacities in Patients With Coronary Artery Disease Undergoing Lifestyle Modification Therapy.
    Boyer M; Lévesque V; Poirier P; Marette A; Mitchell PL; Mora S; Mathieu P; Després JP; Larose É; Arsenault BJ
    J Am Heart Assoc; 2018 Jun; 7(11):. PubMed ID: 29858367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of a one-year lifestyle modification program on cholesterol efflux capacities in men with abdominal obesity and dyslipidemia.
    Boyer M; Mitchell PL; Poirier P; Alméras N; Tremblay A; Bergeron J; Després JP; Arsenault BJ
    Am J Physiol Endocrinol Metab; 2018 Oct; 315(4):E460-E468. PubMed ID: 29870675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of a 1-year lifestyle modification program on plasma lipoprotein and PCSK9 concentrations in patients with coronary artery disease.
    Boyer M; Lévesque V; Poirier P; Marette A; Mathieu P; Després JP; Larose É; Arsenault BJ
    J Clin Lipidol; 2016; 10(6):1353-1361. PubMed ID: 27919352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients.
    Franceschini G; Favari E; Calabresi L; Simonelli S; Bondioli A; Adorni MP; Zimetti F; Gomaraschi M; Coutant K; Rossomanno S; Niesor EJ; Bernini F; Benghozi R
    J Clin Lipidol; 2013; 7(5):414-22. PubMed ID: 24079282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bariatric surgery improves lipoprotein profile in morbidly obese patients by reducing LDL cholesterol, apoB, and SAA/PON1 ratio, increasing HDL cholesterol, but has no effect on cholesterol efflux capacity.
    Kjellmo CA; Karlsson H; Nestvold TK; Ljunggren S; Cederbrant K; Marcusson-Ståhl M; Mathisen M; Lappegård KT; Hovland A
    J Clin Lipidol; 2018; 12(1):193-202. PubMed ID: 29146227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coronary plaque regression and lifestyle modification in patients treated with pravastatin. - Assessment mainly by daily aerobic exercise and an increase in the serum level of high-density lipoprotein cholesterol -.
    Tani S; Nagao K; Anazawa T; Kawamata H; Furuya S; Takahashi H; Iida K; Matsumoto M; Washio T; Kumabe N; Hirayama A
    Circ J; 2010 May; 74(5):954-61. PubMed ID: 20234098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-density lipoprotein cholesterol efflux capacity as a relevant predictor of atherosclerotic coronary disease.
    Ishikawa T; Ayaori M; Uto-Kondo H; Nakajima T; Mutoh M; Ikewaki K
    Atherosclerosis; 2015 Sep; 242(1):318-22. PubMed ID: 26246268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistent changes in lipoprotein lipids after a single infusion of ascending doses of MDCO-216 (apoA-IMilano/POPC) in healthy volunteers and stable coronary artery disease patients.
    Kempen HJ; Gomaraschi M; Simonelli S; Calabresi L; Moerland M; Otvos J; Jeyarajah E; Kallend D; Wijngaard PLJ
    Atherosclerosis; 2016 Dec; 255():17-24. PubMed ID: 27816804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved identification of patients with coronary artery disease by the use of new lipid and lipoprotein biomarkers.
    Johnston N; Jernberg T; Lagerqvist B; Siegbahn A; Wallentin L
    Am J Cardiol; 2006 Mar; 97(5):640-5. PubMed ID: 16490429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-Density Lipoprotein Subfractions and Cholesterol Efflux Capacities After Infusion of MDCO-216 (Apolipoprotein A-IMilano/Palmitoyl-Oleoyl-Phosphatidylcholine) in Healthy Volunteers and Stable Coronary Artery Disease Patients.
    Kempen HJ; Asztalos BF; Moerland M; Jeyarajah E; Otvos J; Kallend DG; Bellibas SE; Wijngaard PL
    Arterioscler Thromb Vasc Biol; 2016 Apr; 36(4):736-42. PubMed ID: 26916733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of the percentage of cholesterol efflux capacity and total cholesterol efflux capacity in patients with or without coronary artery disease.
    Norimatsu K; Kuwano T; Miura SI; Shimizu T; Shiga Y; Suematsu Y; Miyase Y; Adachi S; Nakamura A; Imaizumi S; Iwata A; Nishikawa H; Uehara Y; Saku K
    Heart Vessels; 2017 Jan; 32(1):30-38. PubMed ID: 27106918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of links between high-density lipoprotein genetics, functionality, and aortic valve stenosis risk in humans.
    Arsenault BJ; Dubé MP; Brodeur MR; de Oliveira Moraes AB; Lavoie V; Kernaleguen AE; Guauque-Olarte S; Mathieu P; Pibarot P; Messika-Zeitoun D; Bossé Y; Rhainds D; Rhéaume E; Tardif JC
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):457-62. PubMed ID: 24334872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study.
    Parish S; Offer A; Clarke R; Hopewell JC; Hill MR; Otvos JD; Armitage J; Collins R;
    Circulation; 2012 May; 125(20):2469-78. PubMed ID: 22539783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients With Coronary Endothelial Dysfunction Have Impaired Cholesterol Efflux Capacity and Reduced HDL Particle Concentration.
    Monette JS; Hutchins PM; Ronsein GE; Wimberger J; Irwin AD; Tang C; Sara JD; Shao B; Vaisar T; Lerman A; Heinecke JW
    Circ Res; 2016 Jun; 119(1):83-90. PubMed ID: 27114438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between plasma phospholipase A2 concentrations and lipoprotein subfractions in patients with stable coronary artery disease.
    Xu RX; Zhang Y; Li XL; Li S; Guo YL; Dong Q; Liu G; Li JJ
    Clin Chim Acta; 2015 Jun; 446():195-200. PubMed ID: 25934512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals.
    Nakamura T; Obata JE; Hirano M; Kitta Y; Fujioka D; Saito Y; Kawabata K; Watanabe K; Watanabe Y; Mishina H; Kugiyama K
    Atherosclerosis; 2011 Sep; 218(1):163-7. PubMed ID: 21605862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses.
    van Capelleveen JC; Kastelein JJ; Zwinderman AH; van Deventer SJ; Collins HL; Adelman SJ; Round P; Ford J; Rader DJ; Hovingh GK
    J Clin Lipidol; 2016; 10(5):1137-1144.e3. PubMed ID: 27678430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of hormonal contraception and weight loss on high-density lipoprotein cholesterol efflux and lipoprotein particles in women with polycystic ovary syndrome.
    Dokras A; Playford M; Kris-Etherton PM; Kunselman AR; Stetter CM; Williams NI; Gnatuk CL; Estes SJ; Sarwer DB; Allison KC; Coutifaris C; Mehta N; Legro RS
    Clin Endocrinol (Oxf); 2017 May; 86(5):739-746. PubMed ID: 28199736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-Density Lipoprotein Particle Concentration and Size Predict Incident Coronary Artery Disease Events in a Cohort With Type 1 Diabetes.
    Costacou T; Vaisar T; Miller RG; Davidson WS; Heinecke JW; Orchard TJ; Bornfeldt KE
    J Am Heart Assoc; 2024 Jul; 13(14):e034763. PubMed ID: 38958152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients.
    Yadav R; Liu Y; Kwok S; Hama S; France M; Eatough R; Pemberton P; Schofield J; Siahmansur TJ; Malik R; Ammori BA; Issa B; Younis N; Donn R; Stevens A; Durrington P; Soran H
    J Am Heart Assoc; 2015 Sep; 4(9):e001508. PubMed ID: 26374297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.